The Company has informed that Dr. Md. Afzal Miah, one of the Sponsors of the Company, passed away on 02.08.2025. His entire holding of 110,000 shares of the Company will be transmitted to the account of his nominee, Md. Ashfaque Hussain Suhag (son of Late Dr. Md. Afzal Miah) by way of nomination.

(Q3 Un-audited): EPS was Tk. 0.05 for January-March 2026 as against Tk. 0.13 for January-March 2025; EPS was Tk. 0.32 for July 2025-March 2026 as against Tk. 0.40 for July 2024-March 2025. NOCFPS was Tk. 0.67 for July 2025-March 2026 as against Tk. 0.71 for July 2024-March 2025. NAV per share was Tk. 23.27 as on March 31, 2026 and Tk. 23.02 as on June 30, 2025.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:30 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

The Company has been placed in 'B' category from existing 'Z' category with effect from today i.e., March 11, 2026 as the Company has reported disbursement of 1.10% Cash Dividend for the year ended June 30, 2025.

The Company has been placed in 'Z' category from existing 'B' category with effect from today i.e., March 03, 2026 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024 regarding non-disbursement of the approved dividend within the stipulated time frame.

The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase securities of Silco Pharmaceuticals Limited with effect from today i.e., March 03, 2026 as per rule 11(8) of Bangladesh Securities and Exchange Commission (Margin) Rules, 2025.

(Q2 Un-audited): EPS was Tk. 0.11 for October-December 2025 as against Tk. 0.10 for October-December 2024; EPS was Tk. 0.27 for July-December 2025 as against Tk. 0.27 for July-December 2024. NOCFPS was Tk. 0.51 for July-December 2025 as against Tk. 0.62 for July-December 2024. NAV per share was Tk. 23.29 as on December 31, 2025 and Tk. 23.02 as on June 30, 2025.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:30 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.

The auditor of the company has given the Emphasis of Matters paragraph in the audited financial statements of the company for the year ended June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silco%20Pharmaceuticals%20Limited_2025.pdf

Trading of the shares of the company will resume on 17.12.2025.